Neutrophil to Lymphocyte Ratio as a Biomarker of Severity in Myasthenia Gravis: A Systematic Review and Meta-Analysis
European Neurology · 2026-11-06
DOI: 10.1159/ene/acsag013 ↗Abstract
Abstract Introduction With its increasing prevalence, myasthenia gravis requires reliable prognostic tools. Neutrophil-lymphocte ratio (NLR) offers a simple inflammatory marker to aid early risk evaluation. This meta-analysis aimed to clarify the role of NLR in predicting MG outcomes to support earlier clinical risk stratification. Methods A comprehensive search of PubMed, ScienceDirect, Google Scholar, and Europe PMC were conducted from inception to November 2025. Studies were included if they compared NLR between MG patients and controls or evaluated its prognostic value, while nonclinical research, case reports, reviews, conference abstracts, and non-English papers were excluded. Secondary outcomes were other inflammatory measures, such as white blood cell counts, blood cell differentials, platelet–lymphocyte ratio (PLR), and lymphocyte–monocyte ratio (LMR). Methodological quality was assessed using the QUADAS-2 tool. Results Seven retrospective cohort studies including 1,526 participants were evaluated. Patients with MG had significantly increased white blood cell counts [WMD 1.00 (95% CI: 0.63–1.37; I² = 0%)], neutrophil counts [MD 0.75 (95% CI: 0.15–1.36; I² = 0%)], and NLR values [MD 0.52 (95% CI: 0.07–0.96; I² = 63%)]. No consistent differences were observed in lymphocyte or monocyte counts. Platelet levels were similar, though PLR was generally higher and LMR lower in MG patients. Diagnostic analysis demonstrated that NLR reliably predicted severe MG, with pooled sensitivity of 0.82, specificity of 0.71, and AUC of 0.85. Conclusions NLR is associated with disease severity in MG. NLR may serve as a simple, accessible, and cost-effective marker for disease activity.
EUVIMED